This review provides an overview of the clinical features and treatment options for COVID-19, caused by the SARS-CoV-2 virus. The virus, which belongs to the same family as SARS-CoV and MERS-CoV, has spread globally, leading the WHO to declare a pandemic. The disease presents flu-like symptoms, which can become severe in high-risk individuals. Transmission occurs through human-to-human contact and contaminated surfaces, with hand hygiene and PPE being essential in preventing spread. Common symptoms include fever, cough, fatigue, and dyspnoea, while real-time PCR is used for diagnosis, and CT scans are important for both diagnosis and follow-up. There is currently no effective treatment for COVID-19, and the main therapies include antiviral drugs, chloroquine/hydroxychloroquine, and respiratory therapy. Quarantine is the only intervention shown to effectively reduce contagion. Randomized clinical trials are needed to determine the most effective treatment. The virus can persist on surfaces for up to 9 days, but is inactivated quickly with disinfectants. The average reproduction number (R0) is around 2.5–2.9, indicating the virus's high transmissibility. The clinical presentation of COVID-19 begins within 14 days of exposure, with symptoms typically appearing after 5 days. The mortality rate varies, with estimates ranging from 2% to 5%. The main risk factors for poor outcomes include age, hypertension, diabetes, and chronic lung disease. Diagnosis involves RT-PCR using nasal swabs, tracheal aspirate, or BAL samples. Laboratory tests show common abnormalities such as leucopenia, lymphopenia, and elevated liver enzymes. Radiological findings include ground-glass opacities and consolidation on CT scans. Clinical management focuses on supportive care, with oxygen therapy and mechanical ventilation for severe cases. Antiviral drugs such as remdesivir and lopinavir/ritonavir are being tested, while chloroquine/hydroxychloroquine show some promise but require further study. Respiratory therapy is essential for patients with hypoxia or respiratory distress. The review highlights the need for further research to determine the most effective treatments and to develop vaccines. The only proven intervention to reduce contagion is strict quarantine. The global health and economic consequences of the pandemic are severe, and containment remains the cornerstone of management.This review provides an overview of the clinical features and treatment options for COVID-19, caused by the SARS-CoV-2 virus. The virus, which belongs to the same family as SARS-CoV and MERS-CoV, has spread globally, leading the WHO to declare a pandemic. The disease presents flu-like symptoms, which can become severe in high-risk individuals. Transmission occurs through human-to-human contact and contaminated surfaces, with hand hygiene and PPE being essential in preventing spread. Common symptoms include fever, cough, fatigue, and dyspnoea, while real-time PCR is used for diagnosis, and CT scans are important for both diagnosis and follow-up. There is currently no effective treatment for COVID-19, and the main therapies include antiviral drugs, chloroquine/hydroxychloroquine, and respiratory therapy. Quarantine is the only intervention shown to effectively reduce contagion. Randomized clinical trials are needed to determine the most effective treatment. The virus can persist on surfaces for up to 9 days, but is inactivated quickly with disinfectants. The average reproduction number (R0) is around 2.5–2.9, indicating the virus's high transmissibility. The clinical presentation of COVID-19 begins within 14 days of exposure, with symptoms typically appearing after 5 days. The mortality rate varies, with estimates ranging from 2% to 5%. The main risk factors for poor outcomes include age, hypertension, diabetes, and chronic lung disease. Diagnosis involves RT-PCR using nasal swabs, tracheal aspirate, or BAL samples. Laboratory tests show common abnormalities such as leucopenia, lymphopenia, and elevated liver enzymes. Radiological findings include ground-glass opacities and consolidation on CT scans. Clinical management focuses on supportive care, with oxygen therapy and mechanical ventilation for severe cases. Antiviral drugs such as remdesivir and lopinavir/ritonavir are being tested, while chloroquine/hydroxychloroquine show some promise but require further study. Respiratory therapy is essential for patients with hypoxia or respiratory distress. The review highlights the need for further research to determine the most effective treatments and to develop vaccines. The only proven intervention to reduce contagion is strict quarantine. The global health and economic consequences of the pandemic are severe, and containment remains the cornerstone of management.